You are using an older browser version. Please use a supported version for the best MSN experience.

HEAT BIOLOGICS, INC.

NASDAQ: HTBX
0.7512
-0.0027
-0.36%

Sector

Healthcare

Industry

Biotechnology & Medical Research

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Key People

Jeffrey Wolf

Chairman of the Board, Chief Executive Officer

Jeff Hutchins

Chief Operating Officer, Chief Scientific Officer

Ann Rosar

Vice President - Finance, Corporate Secretary

John Prendergast

Independent Lead Director

John Monahan

Independent Director

  • Heat Biologics Inc

  • 801 Capitola Dr

  • DURHAM, NC 27713-4382

  • US.Map

  • Phone: +1 919 2407133

  • Fax: +1 302 6365454

  • heatbio.com

Incorporated

2008

Employees

30

Insider Trades
  • Recent
  • All
  • Date

  • Name

  • Transaction

  • Shares

  • Price(s)

  • Value

    • 1/1/2019

    • PRENDERGAST JOHN K A

    • Grant

    • 300,000

    • NA

    • NA

    • 1/1/2019

    • ROSAR ANN A

    • Grant

    • 89,430

    • NA

    • NA

    • 1/1/2019

    • WOLF JEFFREY ALAN

    • Grant

    • 800,000

    • NA

    • NA

    • 1/1/2019

    • HUTCHINS JEFF TOBIN PH.D.

    • Grant

    • 143,140

    • NA

    • NA

    • Date

    • Name

    • Transaction

    • Shares

    • Price(s)

    • Value

      • 1/1/2019

      • PRENDERGAST JOHN K A

      • Grant

      • 300,000

      • NA

      • NA

      • 1/1/2019

      • ROSAR ANN A

      • Grant

      • 89,430

      • NA

      • NA

      • 1/1/2019

      • WOLF JEFFREY ALAN

      • Grant

      • 800,000

      • NA

      • NA

      • 1/1/2019

      • HUTCHINS JEFF TOBIN PH.D.

      • Grant

      • 143,140

      • NA

      • NA

      AdChoices
      AdChoices
      AdChoices
      image beaconimage beaconimage beacon